Self-Assembled Indomethacin Dimer Nanoparticles Loaded with Doxorubicin for Combination Therapy in Resistant Breast Cancer
Source abstract
Abstract
An ortho-ester-linked indomethacin (IND) dimer-based nanodrug delivery system was prepared to improve the therapeutic effect of doxorubicin (DOX) by reversing the multidrug resistance. The synthesized dimer (IND-OE) could form stable nanoparticles (IND-OE/DOX) loaded with DOX via the single-emulsion method. Compare to insensitive nanoparticles (IND-C12/DOX), IND-OE/DOX showed a rapid degradation behavior and accelerated drug release at mildly acidic environments. In vitro cell experiments verified that IND-OE nanoparticles could increase DOX concentration due to the efficient intracellular drug release by the degradation of the ortho ester as well as reduced DOX efflux by IND-mediated P-gp downregulation. In vivo studies further demonstrated that IND-OE/DOX displayed the maximized synergetic antitumor efficacy than free DOX or IND-C12/DOX, and the tumor inhibition rates versus saline were 46.78% (free DOX), 60.23% (IND-C12/DOX), and 80.62% (IND-OE/DOX). Overall, this strategy of combination with chemosensitizers and ortho ester linkage has great potential to serve as an amplifying chemotherapy platform against various drug-resistant tumors.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Engineering Research Center for Biomedical Materials, Anhui Key Laboratory of Modern Biomanufacturing, School of Life Sciences, Anhui University, 111 Jiulong Road, Hefei, Anhui Province 230601, P. R. China
Funding
Anhui University · National Natural Science Foundation of China · Anhui Department of Education
References (52)
Show source-provided references
1. 10.1016/j.jconrel.2017.02.02010.1016/j.jconrel.2017.02.020 ↗
2. 10.2174/13892000979027454010.2174/138920009790274540 ↗
3. 10.1158/0008-5472.CAN-15-314310.1158/0008-5472.CAN-15-3143 ↗
4. 10.1038/nrc372610.1038/nrc3726 ↗
5. 10.1016/j.ijpharm.2014.12.01810.1016/j.ijpharm.2014.12.018 ↗
6. 10.3109/10717544.2014.99065110.3109/10717544.2014.990651 ↗
7. 10.1021/ja207150n10.1021/ja207150n ↗
8. 10.1016/j.jcis.2010.12.00410.1016/j.jcis.2010.12.004 ↗
9. 10.1021/acsami.8b1164510.1021/acsami.8b11645 ↗
10. 10.1080/17425247.2016.121323810.1080/17425247.2016.1213238 ↗
11. 10.1080/1061186X.2017.137952510.1080/1061186X.2017.1379525 ↗
12. 10.1111/jcpt.1235510.1111/jcpt.12355 ↗
13. Fan G. F. · Eur. Rev. Med. Pharmacol. · 2018 · 22 · 5508
14. 10.1177/074823371245606510.1177/0748233712456065 ↗
15. 10.1016/j.addr.2012.09.03810.1016/j.addr.2012.09.038 ↗
16. 10.1016/j.jconrel.2016.03.03710.1016/j.jconrel.2016.03.037 ↗
17. 10.1021/ja505212y10.1021/ja505212y ↗
18. 10.1039/C4TB01084A10.1039/C4TB01084A ↗
19. 10.1021/bc100154g10.1021/bc100154g ↗
20. 10.1021/acsami.5b0534710.1021/acsami.5b05347 ↗
21. 10.1021/acsnano.5b0251310.1021/acsnano.5b02513 ↗
22. 10.1016/j.nano.2016.06.01210.1016/j.nano.2016.06.012 ↗
23. 10.1021/nl502044x10.1021/nl502044x ↗
24. 10.1038/srep3661410.1038/srep36614 ↗
25. 10.1039/C7BM00052A10.1039/C7BM00052A ↗
26. 10.1021/acs.chemmater.6b0164110.1021/acs.chemmater.6b01641 ↗
27. 10.1016/j.jconrel.2017.03.39110.1016/j.jconrel.2017.03.391 ↗
28. 10.1016/j.cca.2009.12.02610.1016/j.cca.2009.12.026 ↗
29. 10.1038/nrd192910.1038/nrd1929 ↗
30. 10.1158/0008-5472.CAN-06-395210.1158/0008-5472.CAN-06-3952 ↗
31. 10.3390/molecules1806658410.3390/molecules18066584 ↗
32. 10.1016/j.canlet.2011.01.02510.1016/j.canlet.2011.01.025 ↗
33. 10.1007/s00280-005-0162-910.1007/s00280-005-0162-9 ↗
34. 10.1021/jm049909910.1021/jm0499099 ↗
35. 10.1016/j.actbio.2017.05.01210.1016/j.actbio.2017.05.012 ↗
36. 10.2147/IJN.S14122910.2147/IJN.S141229 ↗
37. 10.1021/acsami.5b0168710.1021/acsami.5b01687 ↗
38. 10.1016/j.eurpolymj.2017.08.02310.1016/j.eurpolymj.2017.08.023 ↗
39. 10.1016/j.biotechadv.2013.11.00910.1016/j.biotechadv.2013.11.009 ↗
40. 10.1016/j.biomaterials.2016.04.00110.1016/j.biomaterials.2016.04.001 ↗
41. 10.3390/polym1008089510.3390/polym10080895 ↗
42. 10.1016/j.ijbiomac.2018.04.07610.1016/j.ijbiomac.2018.04.076 ↗
43. Liang X. J. · Cancer Res. · 2003 · 63 · 5909
44. 10.1002/mabi.20160050310.1002/mabi.201600503 ↗
45. 10.1016/j.jconrel.2018.07.02810.1016/j.jconrel.2018.07.028 ↗
46. 10.1016/j.cell.2017.12.00510.1016/j.cell.2017.12.005 ↗
47. 10.1016/j.jinorgbio.2017.07.00210.1016/j.jinorgbio.2017.07.002 ↗
48. 10.1016/j.ijpharm.2015.10.00910.1016/j.ijpharm.2015.10.009 ↗
49. 10.1016/j.addr.2013.08.00410.1016/j.addr.2013.08.004 ↗
50. 10.1016/j.addr.2010.04.00910.1016/j.addr.2010.04.009 ↗
51. 10.1002/adma.20150220110.1002/adma.201502201 ↗
52. 10.1002/adma.20170014110.1002/adma.201700141 ↗